title: Thrombosis in the pediatric population.
abstract: Whereas thrombotic events in critically ill children do not occur as commonly as in adults, they are being recognized with increasing frequency in the pediatric intensive care unit. The reasons for this are not clear but likely include an increased awareness of the problem and the ability to make a diagnosis using relatively noninvasive tests. In this section, I attempt to define the extent of the problem, summarize and discuss the relevant literature (pointing out where published experience in the pediatric population differs from that in adult patients), and suggest some guidelines regarding thrombophilia treatment and the management of thrombotic events.
authors.affiliation: Department of Pediatrics, SUNY at Stony Brook School of Medicine, Stony Brook, NY, USA. robert.parker@stonybrook.edu
authors.forename: Robert I
authors.initials: RI
authors.lastname: Parker
mesh_terms: D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications; D016736:Antiphospholipid Syndrome / Q000150:complications; D001327:Autoimmune Diseases / Q000150:complications; D002408:Catheters, Indwelling / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006330:Heart Defects, Congenital / Q000150:complications; D006801:Humans; D007223:Infant; D009369:Neoplasms / Q000150:complications; D009404:Nephrotic Syndrome / Q000150:complications; D011655:Pulmonary Embolism / Q000209:etiology; D012307:Risk Factors; D019851:Thrombophilia / Q000150:complications / Q000175:diagnosis; D013927:Thrombosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*
chemical_list: D005343:Fibrinolytic Agents